Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China
· Delayed Price · Currency is CNY 7.42
-0.82 (-9.95%)
Apr 25, 2025, 2:45 PM CST
SHE:002581 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 360.41 | 425.78 | 356.18 | 397.44 | 274.72 | Upgrade
|
| Other Revenue | - | 4.01 | 0.9 | 5.27 | 2.11 | Upgrade
|
| Revenue | 360.41 | 429.79 | 357.08 | 402.71 | 276.83 | Upgrade
|
| Revenue Growth (YoY) | -16.14% | 20.36% | -11.33% | 45.47% | -51.23% | Upgrade
|
| Cost of Revenue | 72.86 | 93.29 | 76.64 | 85.83 | 54.88 | Upgrade
|
| Gross Profit | 287.55 | 336.5 | 280.44 | 316.88 | 221.95 | Upgrade
|
| Selling, General & Admin | 336.65 | 453.3 | 426.21 | 477.76 | 414.31 | Upgrade
|
| Research & Development | 25.37 | 59.8 | 27.29 | 38.44 | 49.3 | Upgrade
|
| Other Operating Expenses | 5.76 | 6.78 | 6.24 | 6.83 | 6.63 | Upgrade
|
| Operating Expenses | 367.78 | 492.32 | 456.02 | 520.83 | 482.29 | Upgrade
|
| Operating Income | -80.24 | -155.81 | -175.57 | -203.95 | -260.34 | Upgrade
|
| Interest Expense | - | -8.67 | -9.41 | -6.88 | -25.43 | Upgrade
|
| Interest & Investment Income | - | 1.72 | 3.02 | 3.75 | 17.2 | Upgrade
|
| Earnings From Equity Investments | 62.73 | 172.68 | 217.45 | 471.94 | 109.61 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | 0 | -0.01 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -25.32 | -10.21 | 0.22 | -6.68 | -5.38 | Upgrade
|
| EBT Excluding Unusual Items | -42.83 | -0.29 | 35.72 | 258.18 | -164.34 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -20.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.16 | -6.33 | 0.05 | -0.15 | -22.69 | Upgrade
|
| Asset Writedown | -104.5 | -293.88 | -13.61 | -0.48 | -6.59 | Upgrade
|
| Legal Settlements | - | - | -15.49 | - | - | Upgrade
|
| Other Unusual Items | - | -12.76 | 6.05 | 21.05 | 12.29 | Upgrade
|
| Pretax Income | -146.18 | -313.25 | 12.72 | 278.6 | -201.76 | Upgrade
|
| Income Tax Expense | -3.34 | 8.89 | 13.58 | -0.09 | -3.59 | Upgrade
|
| Earnings From Continuing Operations | -142.84 | -322.14 | -0.86 | 278.69 | -198.18 | Upgrade
|
| Minority Interest in Earnings | 5.52 | -10.32 | -13.82 | -7.69 | 2.24 | Upgrade
|
| Net Income | -137.31 | -332.46 | -14.68 | 271 | -195.93 | Upgrade
|
| Net Income to Common | -137.31 | -332.46 | -14.68 | 271 | -195.93 | Upgrade
|
| Shares Outstanding (Basic) | 660 | 660 | 658 | 660 | 660 | Upgrade
|
| Shares Outstanding (Diluted) | 660 | 660 | 658 | 660 | 660 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.22% | -0.21% | -0.00% | 0.02% | Upgrade
|
| EPS (Basic) | -0.21 | -0.50 | -0.02 | 0.41 | -0.30 | Upgrade
|
| EPS (Diluted) | -0.21 | -0.50 | -0.02 | 0.41 | -0.30 | Upgrade
|
| Free Cash Flow | -15.56 | -40.82 | -85.95 | -106.86 | -49.19 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.06 | -0.13 | -0.16 | -0.07 | Upgrade
|
| Gross Margin | 79.78% | 78.30% | 78.54% | 78.69% | 80.18% | Upgrade
|
| Operating Margin | -22.26% | -36.25% | -49.17% | -50.64% | -94.04% | Upgrade
|
| Profit Margin | -38.10% | -77.35% | -4.11% | 67.29% | -70.78% | Upgrade
|
| Free Cash Flow Margin | -4.32% | -9.50% | -24.07% | -26.53% | -17.77% | Upgrade
|
| EBITDA | -39.08 | -87.43 | -110.63 | -144.38 | -200.66 | Upgrade
|
| EBITDA Margin | -10.84% | -20.34% | -30.98% | -35.85% | -72.48% | Upgrade
|
| D&A For EBITDA | 41.16 | 68.39 | 64.95 | 59.57 | 59.68 | Upgrade
|
| EBIT | -80.24 | -155.81 | -175.57 | -203.95 | -260.34 | Upgrade
|
| EBIT Margin | -22.26% | -36.25% | -49.17% | -50.64% | -94.04% | Upgrade
|
| Effective Tax Rate | - | - | 106.75% | - | - | Upgrade
|
| Revenue as Reported | - | 429.79 | 357.08 | 402.71 | 276.83 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.